Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • glises581g glises581g Aug 1, 2013 11:50 AM Flag

    The jury is out on the data

    The data released is preliminary and yet to be discussed within the regulatory bodies or scientific community.Initial reaction is the drug works well with less severe patients and will be among choices but certainly not a "leader"as has been characterized here.This is not the indication that will make Insmed anything more than niche.NTM may.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 1users liked this postsusers disliked this posts2Reply
      The jury is out on the data
      by glises581g • Aug 1, 2013 11:50 AM Flag
      The data released is preliminary and yet to be discussed within the regulatory bodies or scientific community.Initial reaction is the drug works well with less severe patients and will be among choices but certainly not a "leader"as has been characterized here.This is not the indication that will make Insmed anything more than niche.NTM may.

    • There have been no regulatory or scientific peer review of the phase three results/ so no one including self
      proclaimed experts have any information yet./ Mr Lewis may give the company's position and targets,but the
      data analyzed by those in the scientific community and the regulatory bodies will decide the drugs
      benefits ,side effects or lack thereof.

    • Give it up. This argument has been thoroughly dispelled over the past month.

      Sentiment: Buy

 
INSM
25.66-0.50(-1.91%)Jul 27 4:00 PMEDT